
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid
Keywords: Ibrutinib; Dihydrodiol-ibrutinib; LC-MS/MS; Cerebrospinal fluid; B-cell malignancies;